switching glp 1 Patients without diabetes who switched between glucagon-like peptide-1 receptor agonist (GLP-1RA) medications for overweight or obesity were more likely to remain engaged with treatment than those who stayed on the same medication Lilly widens GLP-1 lead—for now

Athletes need support rather than judgment, says Kelly Jones, RD, a sports dietetics specialist and owner of Kelly Jones Nutrition and Student Athlete Nutrition

In the STEP UP trial, adults living with obesity who received semaglutide 7.2mg achieved an average weight loss of 18.7% over 72 weeks, compared with 15.6% with 2.4mg and 3.9% with placebo

[DOI] [PubMed] [Google Scholar] 27.Dmaso A.R., Do Prado W.L., De Piano A., et al

Eli Lilly, on the other hand, is making strides with its clinically superior drugs and is expected to surpass Novo Nordisk

Its a once-daily pill and will now become available for private prescription, but it still under review by the National Institute for Health and Care Excellence (NICE) for use in the NHS

This story was produced by GoodRx and reviewed and distributed by Stacker.